GlobeNewswire

Cappasity Starts ARToken crowdsale and Adds Cryptocurrency Expert David Drake to its Advisory Board

Dela

SANTA CLARA, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Cappasity, a company that develops a platform and an AR/VR blockchain ecosystem for 3D content production and mass distribution, is announcing the start of a crowdsale of ARToken (AR) on October 25, at 1 PM UTC. David Drake, Chairman at LDJ Capital, joins Cappasity's advisory board to provide counsel on critical issues relating to the specifics of the ICO process, blockchain and investor relations.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/aaaee806-98e3-476f-90ce-eb06e91d7e43

Today, Cappasity is announcing the start of the crowdsale of ARToken - a new digital currency that will be used as the primary payment unit within the global decentralized AR/VR Ecosystem for 3D content exchange.

As a token sale is a very important step for the development of the company's project, Cappasity has decided to consult the deep expertise of one of the leading specialists in blockchain, cryptocurrency and international business development - David Drake, Chairman at LDJ Capital. David has shown his strong interest in the project and joined Cappasity's advisory board.

David Drake is the Chairman of LDJ Capital, a family office; Victoria Partners, LDJ Real Estate Group; Drake Hospitality Group; and, The Soho Loft Media Group. LDJ Capital's extended network of funds of funds and hedge funds manages 1.5 trillion USD in assets. Mr. Drake's access to 100,000 investors is maintained through his media holding investment, The Soho Loft Media Group which has produced and sponsored over 1500+ global finance conferences since 2002. David is actively involved in the Crypto community as a speaker and has helped ICO firms he advised raise in excess of $100M in funding.

"AR/VR market is rapidly growing, with diverse content being the driving force behind the industry's growth. I found the project by Cappasity having every chance to come off since Cappasity creates a convenient environment where high-quality 3D content will be produced in large amounts. I am really glad to share my expertise with Cappasity to help bring future changes into the industry," said David Drake, Partner at LDJ Capital.

"3D content is becoming a critical component in multiple verticals including gaming, entertainment, retail, art, education, and health. Cappasity will leverage the blockchain to become the global 3D/AR/VR content exchange ecosystem for the users, developers and businesses who will benefit from 3D image creation, embedding and trading," noted Kosta Popov, Cappasity founder and CEO. "We are excited to bring innovative content creators the opportunity to participate in the AR/VR content revolution with the utility ARToken (ART) to power the whole ecosystem."

The ARToken crowdsale begins on the 25th of October and will last for 4 weeks. Cappasity platform, a beta-version of which was released in January 2017, plans to attract a total of $30m within Phase 1. The latter is divided into three tiers. Tier 1 allows participants to get up to a 20% bonus. Total investment in the company from VC funds and angel investors so far amounted to $1.8m.


MEDIA INQUIRIES
Jenny Herz
info@cappasity.com

Website - https://www.artoken.io
Twitter - https://twitter.com/cappasity
Facebook - https://www.facebook.com/cappasity
Telegram - https://t.me/artoken
Linkedin - https://www.linkedin.com/company/cappasity-inc-




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cappasity Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Stillfront Group rekryterar ansvarig för M&A19.12.2018 12:07Pressmeddelande

PRESSMEDDELANDE 19 december, 2018 Stillfront Group rekryterar ansvarig för M&A Stillfront Group, en marknadsledare inom 'free to play' online strategispel, annonserar idag att Marina Andersson har utsetts till ansvarig för M&A och kommer att ingå i koncernledningen. Marina har närmare tjugo års erfarenhet från investment banking och M&A. Hon har omfattande erfarenhet inom strategisk och finansiell rådgivning, affärsgenerering, projektledning inom förvärv och försäljningar av företag, finansiell analys, due diligence, samt företagsvärdering. Tidigare positioner inkluderar: Director, Deloitte's Corporate Finance Advisory team, Director, ICECAPITAL Securities, Associate Partner och Investment Manager, Deseven, samt M&A Analytiker på Carnegie. Marina har två magister-examen från Stockholms universitet och Russian Herzen State Pedagogical University. "Förvärv är en viktig del av Stillfronts affärsstrategi och vi är mycket glada att rekrytera Marina Andersson. Marinas breda erfarenhet och pr

Stillfront Group announces Head of M&A19.12.2018 12:07Pressmeddelande

PRESS RELEASE December 19, 2018 Stillfront Group announces Head of M&A Stillfront Group, a market leader in 'free to play' online strategy games, today announces that Marina Andersson has been appointed as Head of M&A and will be part of the Group's management team. Marina has close to 20 years track record of investment banking and M&A. She has extensive competence within strategic and financial advisory, deal generation, buy and sell side M&A project management, financial analysis, due diligence and company valuation. Former positions include: Director at Deloitte's Corporate Finance Advisory team, Director at ICECAPITAL Securities, Associate Partner and Investment Manager at Deseven, M&A Analyst at Carnegie. She holds two Master degrees from Stockholm University and Russian Herzen State Pedagogical University. "Acquisitions are a crucial part of Stillfront's business strategy and we are very pleased with the appointment of Marina Andersson. Marina's breadth of experience and profess

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum